New Delhi: Emcure Pharmaceuticals shares are projected to rise significantly, Kotak Institutional Equities has stated. The pharma stock jumped 10 per cent on May 23, 2025 to settle at Rs 1,284.40 per equity share. The counter jumped after the brokerage firm shared the target price. It gave a ‘Buy’ rating and set a target price of Rs 1,625 apiece, which indicates a gain percentage of over 35 per cent from the current prices.
Emcure Pharma released its January-March quarter results on 22nd May, mentioning that the company’s earnings increased 19.5 percent year-on-year and 8 percent from the previous quarter. The pharma firm’s EBITDA surged by 29.5 percent, while EBITDA margin stood at 19 per cent, up 150 basis points over the previous year and 90 basis points over the December quarter.
Kotak initiated a Buy rating as Emcure Pharma is one of the few Indian pharmaceutical companies that does not have direct exposure to generic drugs in the US. This makes the company’s earnings more stable and it is less affected by market fluctuations.
Emcure Pharmaceuticals’ revenue from operations in the last quarter of the previous fiscal was recorded at Rs 2,116.2 crore as compared to Rs 1,771.3 crore in the same quarter of 2023-24, up 19 per cent.
The company’s board recommended a final dividend of Rs 3 per equity share of Rs 10 /- (Rupees Ten only) each of the company (at the rate of 30 per cent) for the financial year ended March 31, 2025.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds and crypto assets.)
Kotak Institutional Equities issued a ‘Buy’ rating for Emcure Pharma, predicting a 35%+ price increase to Rs 1625 per share. This follows strong Q4 results showing a 19.5% year-on-year earnings increase and a 29.5% EBITDA surge. Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
